Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00469 | Pages: 276 | Charts: 42 | Tables: 125 |
The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027. Chronic obstructive pulmonary disease (COPD) and asthma devices are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. Moreover, COPD and asthma are the respiratory diseases that cause difficulty in breathing and a blockage in the airways of lungs. Furthermore, according to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.
Get more information on this report : Request Sample Pages
Chronic obstructive pulmonary disease (COPD) and asthma are a chronic inflammatory lung disorder. The COPD and Asthma symptoms & causes are equivalent to the symptoms of the pandemic coronavirus disease 2019. In addition, asthmatic patients are more prone to the Covid-19 symptoms. According to the paper published by the Journal of Allergy and Clinical Immunology, in 2020, the patients with the asthma and COPD appear to have increased their adherence to inhalers medications during the Covid-19. Moreover, according to the National Health Service (NHS) in 2020, the number of inhalers prescribed by general practitioners in England increased by 63% between February 2020 and March 2020. Further, in some parts of the country such as U.K and U.S. are experiencing shortages of albuterol inhalers, because hospitals are using them more for COVID-19 patients. Thus, Covid-19 has uplifted the growth and opportunities for the manufacturers of COPD and Asthma devices during the forecast period.
The major factors that contribute toward the growth of the COPD and asthma devices market include rise in prevalence of respiratory diseases such as COPD, asthma, and emphysema; growing need for rescue medication during sudden asthmatic attack; and burgeoning demand for short-term, effective medication. Moreover, increase in focus of manufacturers toward the development of advanced, portable inhalation devices, and government initiatives toward the spread of awareness for COPD and asthma symptoms are expected to boost the market growth. However, the factors such as environmental concerns associated with metered dose inhalers (MDI), high cost of some inhalation devices and treatment, rise in price competition, and deterioration of material quality are expected to restrain the market growth. In addition, incompetent reimbursement support and patent expiration for blockbuster drugs hamper the market growth. On the contrary, rise in use of the smart inhaler devices that are more intuitive and drive the patient engagement and adherence while increasing treatment effectiveness is anticipated to provide lucrative growth opportunity for the market growth in the near future.
The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries.
On the basis of product type, the market is divided into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. In addition, the inhalers segment held the major COPD and asthma devices market share in 2019, owing to the factors such as inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma.
[PRODUCTTYPEGRAPH]
Get more information on this report : Request Sample Pages
By distribution channel, the retail pharmacies segment occupied the largest COPD and asthma devices market share in 2019 and is also expected to exhibit fastest growth rate during the forecast period. The growth of the segment is due to factors such as it is the oldest and most conventional medium distributing the respiratory devices to the consumers, owing to its large chain of distribution network of pharmacies store.
[DISTRIBUTIONCHANNELGRAPH]
Get more information on this report : Request Sample Pages
In 2019, North America accounted for the major share in 2019 for COPD and asthma devices market size and is expected to continue this trend, owing to the widespread and early adoption of inhalers & nebulizers and large pool of patients suffering from respiratory diseases. Moreover, the Asia-Pacific region is expected to grow rapidly due to rise in healthcare expenditure, growth in awareness of advanced portable COPD & asthma devices, and increase in disposable income.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology
1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.key findings of the study:
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top impacting factors
3.2.2.Top investment pockets
3.2.3.Top winning strategies, 2016-2018
3.3.Porter’s five forces analysis
3.3.1.Moderate bargaining power of buyers
3.3.2.Low bargaining power of suppliers
3.3.3.Moderate threat of substitutes
3.3.4.Low threat of new entrants
3.3.5.Moderate competitive rivalry
3.4.Value chain analysis
3.5.Government regulations
3.5.1.COPD devices regulations in Europe and in the U.S.
3.5.2.COPD devices regulations in Asia-Pacific
3.6.Clinical trials
3.7.Patent analysis
3.7.1.Patent analysis by region
3.7.2.U.S. Patent analysis
3.7.3.Europe patent analysis
3.7.4.Japan patent analysis
3.8.Drivers
3.8.1.Daily exposure to environmental pollution
3.8.2.Increase in population susceptible to indoor air pollutants
3.8.3.Portability of the drug delivery devices
3.8.4.Increasing population of active smokers
3.8.5.Rising government initiatives
3.9.Restraints
3.9.1.Increase in price competition and deterioration of material quality
3.9.2.Overall high cost of asthma treatment is a challenge for the patients
3.9.3.Incompetent reimbursement support
3.10.Opportunities
3.10.1.Patent expiration for blockbuster drugs
3.10.2.Smart Inhaler: future growth driver
CHAPTER 4:COPD AND ASTHMA DEVICES MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Inhalers
4.2.1.Market size and forecast
4.2.2.Market share analysis, by country
4.2.3.Drug powdered inhalers (DPIs)
4.2.3.1.Key market trends and opportunity
4.2.4.Metered dose inhalers (MDIs)
4.2.4.1.Key market trends and opportunity
4.2.5.Soft mist inhalers
4.2.5.1.Key market trends and opportunity
4.3.Nebulizers
4.3.1.Market size and forecast
4.3.2.Market share analysis, by country
4.3.2.1.Compressor nebulizers
4.3.2.2.Ultrasonic nebulizers
4.3.2.3.Mesh nebulizers
CHAPTER 5:COPD AND ASTHMA DEVICES MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Asthma
5.2.1.Market size and forecast
5.2.2.Market share analysis, by country
5.3.COPD
5.3.1.Market size and forecast
5.3.2.Market share analysis, by country
CHAPTER 6:COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Retail Pharmacies
6.2.1.Market size and forecast
6.2.2.Market share analysis, by country
6.3.Hospitals
6.3.1.Market size and forecast
6.3.2.Market share analysis, by country
6.4.Online Pharmacies
6.4.1.Market size and forecast
6.4.2.Market share analysis, by country
CHAPTER 7:COPD & ASTHMA DEVICE MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.North America market size and forecast, by country
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by indication
7.2.5.North America market size and forecast, by distribution channel
7.2.5.1.U.S.
7.2.5.1.1.U.S. market size and forecast, by product
7.2.5.1.2.U.S. market size and forecast, by indication
7.2.5.1.3.U.S. market size and forecast, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada market size and forecast, by product
7.2.5.2.2.Canada market size and forecast, by indication
7.2.5.2.3.Canada market size and forecast, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico market size and forecast, by product
7.2.5.3.2.Mexico market size and forecast, by indication
7.2.5.3.3.Mexico market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Europe market size and forecast, by country
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by indication
7.3.5.Europe market size and forecast, by distribution channel
7.3.5.1.Germany
7.3.5.1.1.Germany market size and forecast, by product
7.3.5.1.2.Germany market size and forecast, by indication
7.3.5.1.3.Germany market size and forecast, by distribution channel
7.3.5.2.UK
7.3.5.2.1.UK market size and forecast, by product
7.3.5.2.2.UK market size and forecast, by indication
7.3.5.2.3.UK market size and forecast, by distribution channel
7.3.5.3.France
7.3.5.3.1.France market size and forecast, by product
7.3.5.3.2.France market size and forecast, by indication
7.3.5.3.3.France market size and forecast, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy market size and forecast, by product
7.3.5.4.2.Italy market size and forecast, by indication
7.3.5.4.3.Italy market size and forecast, by distribution channel
7.3.5.5.Russia
7.3.5.5.1.Russia market size and forecast, by product
7.3.5.5.2.Russia market size and forecast, by indication
7.3.5.5.3.Russia market size and forecast, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe market size and forecast, by product
7.3.5.6.2.Rest of Europe market size and forecast, by indication
7.3.5.6.3.Rest of Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by country
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.4.5.1.Japan
7.4.5.1.1.Japan market size and forecast, by product
7.4.5.1.2.Japan market size and forecast, by indication
7.4.5.1.3.Japan market size and forecast, by distribution channel
7.4.5.2.China
7.4.5.2.1.China market size and forecast, by product
7.4.5.2.2.China market size and forecast, by indication
7.4.5.2.3.China market size and forecast, by distribution channel
7.4.5.3.India
7.4.5.3.1.India market size and forecast, by product
7.4.5.3.2.India market size and forecast, by indication
7.4.5.3.3.India market size and forecast, by distribution channel
7.4.5.4.Australia
7.4.5.4.1.Australia market size and forecast, by product
7.4.5.4.2.Australia market size and forecast, by indication
7.4.5.4.3.Australia market size and forecast, by distribution channel
7.4.5.5.Rest of Asia-Pacific
7.4.5.5.1.Rest of Asia-Pacific market size and forecast, by product
7.4.5.5.2.Rest of Asia-Pacific market size and forecast, by indication
7.4.5.5.3.Rest of Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by country
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by distribution channel
7.5.5.1.Brazil
7.5.5.1.1.Brazil market size and forecast, by product
7.5.5.1.2.Brazil market size and forecast, by indication
7.5.5.1.3.Brazil market size and forecast, by distribution channel
7.5.5.2.Argentina
7.5.5.2.1.Argentina market size and forecast, by product
7.5.5.2.2.Argentina market size and forecast, by indication
7.5.5.2.3.Argentina market size and forecast, by distribution channel
7.5.5.3.Saudi Arabia
7.5.5.3.1.Saudi Arabia market size and forecast, by product
7.5.5.3.2.Saudi Arabia market size and forecast, by indication
7.5.5.3.3.Saudi Arabia market size and forecast, by distribution channel
7.5.5.4.Colombia
7.5.5.4.1.Colombia market size and forecast, by product
7.5.5.4.2.Colombia market size and forecast, by indication
7.5.5.4.3.Colombia market size and forecast, by distribution channel
7.5.5.5.Turkey
7.5.5.5.1.Turkey market size and forecast, by product
7.5.5.5.2.Turkey market size and forecast, by indication
7.5.5.5.3.Turkey market size and forecast, by distribution channel
7.5.5.6.Rest of LAMEA
7.5.5.6.1.Rest of LAMEA market size and forecast, by product
7.5.5.6.2.Rest of LAMEA market size and forecast, by indication
7.5.5.6.3.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.Aerogen, Inc.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.2.AstraZeneca PLC
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Baxter International Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product Portfolio
8.3.5.Business performance
8.4.Boehringer Ingelheim International GmbH
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.3M COMPANY
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.GF Health Products, Inc.
8.6.1.Company overview
8.6.2.Product portfolio
8.7.GlaxoSmithKline Plc
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Koninklijke Philips N.V. (Philips)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Novartis AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.PARI medical Holding GMBH
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
8.11.Smith’s Group Plc
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Business performance
LIST OF TABLES
TABLE 01.CLINICAL TRIALS - COPD AND ASTHMA DEVICES
TABLE 02.COPD AND ASTHMA DEVICES PATENTS
TABLE 03.ADVANTAGES AND DISADVANTAGES OF MARKETED PORTABLE INHALER DEVICES
TABLE 04.PERCENTAGE OF SMOKER POPULATION BY RACE/ETHNICITY, 2016
TABLE 05.COST OF ASTHMA IN BILLION, 2015
TABLE 06.COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 07.RESCUE INHALERS VS MAINTENANCE INHALERS
TABLE 08.COMMON TYPES OF INHALERS
TABLE 09.TOP 10 COPD INHALERS
TABLE 10.INHALERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
TABLE 11.DRY POWDER INHALERS
TABLE 12.TYPES OF METERED DOSE INHALERS (MDIS)
TABLE 13.COMMERCIALIZED NEBULIZERS AND ITS COST
TABLE 14.NEBULIZERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
TABLE 15.COPD AND ASTHMA DEVICES MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 16.ASTHMA COPD ANDS ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 17.COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 18.COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 19.RETAIL PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 20.HOSPITALS COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 21.ONLINE PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 22.GLOBAL COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 23.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 27.U.S. COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 28.U.S. COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.U.S. COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 30.CANADA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 31.CANADA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.CANADA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.MEXICO COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.MEXICO COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 35.MEXICO COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 37.EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 39.GERMANY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 40.GERMANY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.GERMANY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.UK COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 43.UK COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.UK COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 45.FRANCE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 46.FRANCE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.FRANCE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 48.ITALY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.ITALY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 50.ITALY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 51.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 52.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 56.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 61.JAPAN COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.JAPAN COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 63.JAPAN COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.CHINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 65.CHINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.CHINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 67.INDIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 68.INDIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 69.INDIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 70.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 71.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 72.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 76.LAMEA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 78.LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 79.LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 80.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 81.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 82.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 83.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 84.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 85.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 86.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 89.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 90.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 91.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 92.TURKEY COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 93.TURKEY COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 94.TURKEY COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 95.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 96.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 97.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 98.AEROGEN: COMPANY SNAPSHOT
TABLE 99.AEROGEN: PRODUCT PORTFOLIO
TABLE 100.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 101.ASTRAZENECA: OPERATING SEGMENTS
TABLE 102.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 01.BAXTER: COMPANY SNAPSHOT
TABLE 02.BAXTER: BUSINESS UNITS
TABLE 03.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 04.BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 05.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 06.3M: COMPANY SNAPSHOT
TABLE 07.3M: OPERATING BUSINESS SEGMENTS
TABLE 08.3M: PRODUCT PORTFOLIO
TABLE 09.GF HEALTH PRODUCTS: SNAPSHOT
TABLE 10.GF HEALTH PRODUCTS: PRODUCT PORTFOLIO
TABLE 11.GSK.: COMPANY SNAPSHOT
TABLE 12.GSK: OPERATING SEGMENTS
TABLE 13.GSK: PRODUCT PORTFOLIO
TABLE 14.PHILIPS: COMPANY SNAPSHOT
TABLE 15.PHILIPS: OPERATING SEGMENTS
TABLE 16.PHILIPS: PRODUCT PORTFOLIO
TABLE 17.NOVARTIS: COMPANY SNAPSHOT
TABLE 18.NOVARTIS: OPERATING SEGMENTS
TABLE 19.NOVARTIS: PRODUCT PORTFOLIO
TABLE 20.PARI: COMPANY SNAPSHOT
TABLE 21.PARI: PRODUCT PORTFOLIO
TABLE 22.PARI: PRODUCT PORTFOLIO
TABLE 23.SMITHS MEDICAL: COMPANY SNAPSHOT
TABLE 24.SMITHS MEDICAL: OPERATING SEGMENTS
TABLE 25.SMITHS MEDICAL: PRODUCT PORTFOLIOG
LIST OF FIGURES
FIGURE 01.TOP FACTORS IMPACTING GLOBAL COPD AND ASTHMA DEVICES MARKET, 2015–2022
FIGURE 02.TOP INVESTMENT POCKETS OF GLOBAL COPD AND ASTHMA DEVICES MARKET, BY COUNTRY
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016–2018*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2018* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2016-2018* (%)
FIGURE 06.VALUE CHAIN ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES
FIGURE 07.PATENT REGISTRATIONS BY REGION 2011–2014 (%)
FIGURE 08.U.S. PATENT REGISTRATIONS, BY PRODUCT, 2011–2014 (%)
FIGURE 09.EUROPE PATENT REGISTRATIONS, BY PRODUCT 2011–2014 (%)
FIGURE 10.JAPAN PATENT REGISTRATIONS, BY PRODUCT, 2012–2014 (%)
FIGURE 11.THE FOLLOWING FIGURE DEPICTS THE PREVALENCE OF COPD AMONG PEOPLE AGED 45 AND ABOVE, BY AGE AND SEX (2017-2018).
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INHALERS ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NEBULIZERS ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOPSPITALS COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PAYERS COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
FIGURE 19.ASTRAZENECA: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 20.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21.ASTRAZENECA: REVENUE SHARE BY REGION 2018 (%)
FIGURE 22.NET SALES, 2016–2018 ($MILLION)
FIGURE 23.BAXTER: REVENUE SHARE BY BUSINESS UNIT, 2018 (%)
FIGURE 24.BAXTER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25.BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 26.BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27.BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018(%)
FIGURE 28.3M: NET SALES, 2016–2018 ($MILLION)
FIGURE 29.3M: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30.3M: REVENUE SHARE BY REGION, 2018(%)
FIGURE 31.GSK: REVENUE, 2016-2018($MILLION)
FIGURE 32.GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33.GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 34.PHILIPS: NET SALES, 2016–2018 ($MILLION)
FIGURE 35.PHILIPS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36.PHILIPS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 37.NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 38.NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39.NOVARTIS: REVENUE SHARE BY REGION 2018(%)
FIGURE 40.SMITHS MEDICAL: NET SALES, 2016–2018 ($MILLION)
FIGURE 41.SMITHS MEDICAL: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42.SMITHS MEDICAL: REVENUE SHARE BY REGION, 2018 (%)
